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Abstract Objective: There is
considerable heterogeneity among
randomized trials comparing high-
frequency ventilation (HFV) with
conventional mechanical ventilation
(CMV) in premature neonates with
respiratory distress syndrome. We
investigated what factors explained
differences in outcome among these
trials. Design: Meta-regression
analysis of 15 randomized trials.
Measurements and results: Variables
were extracted to explain hetero-
geneity: year of publication; use of
Sensormedics 3100A ventilator for
HFV; time on CMV prior to start
of study; gestational age; use of
surfactant; high lung volume strategy
in HFV; and lung protective ventila-
tion strategy in CMV and baseline
risk. Chronic lung disease (CLD)
and death or CLD were outcome
measures. Relative risk ratios were
calculated to estimate effect sizes
of explanatory variables on reported
relative risks. Adjusted estimates
of relative risk ratios of high lung
volume strategy and lung protective
ventilation strategy were 0.42 (95%
CI 0.06–2.48) and 2.02 (95% CI
0.18–23.12) for CLD, respectively.
The effect of gestational age was less
pronounced (RRR = 1.17 (95% CI
0.16–8.32) for CLD, respectively).
Use of Sensormedics and prior time
on CMV had the smallest effects
[RRR =0.96 (95% CI 0.47–1.94)
and RRR =0.85 (95% CI 0.58–1.24)
for CLD, respectively)]. The same
results applied to CLD or death as
outcome. Conclusions: Variation
in ventilation strategies that were
used in trials comparing HFV with
CMV in premature neonates offered
the most likely explanation for the
observed differences in the outcome
of these trials compared with other
explanatory factors.
Keywords Conventional mechanical
ventilation · High-frequency ventila-
tion · Meta-regression analysis · Res-
piratory distress syndrome · Infant
Introduction
High-frequency ventilation (HFV) has been compared
with conventional mechanical ventilation (CMV) since
the 1980s. In HFV, patients are ventilated with small tidal
volumes, even smaller than the dead space of their air-
ways, at high frequencies, normally between 5and 10Hz.
Because HFV combines high mean airway pressures with
small tidal volumes, this technique of ventilation has been
regarded by some to be the most optimal form in patients
with infant respiratory distress syndrome (IRDS), adult
respiratory distress syndrome (ARDS), and other forms of
severe lung disease [1].
The HFV has been extensively investigated in prema-
ture neonates with IRDS, a population speciﬁcally at risk
for chronic lung disease (CLD). Unfortunately, the results
of these studies were equivocal [2, 3]; thus, the question
remains whether or not HFV better prevents CLD than
conventional mechanical ventilation (CMV) in patients
with severe lung disease. A signiﬁcant number of meta-681
analyses have been performed to answer this question [4,
5, 6, 7, 8]. Pooled estimates of pulmonary outcomes failed
to show clinically relevant differences among HFV and
CMV [7]; however, signiﬁcant heterogeneity existed be-
tween studies included in these meta-analyses. In a recent
cumulative meta-analysis we identiﬁed improvements
of the conventional treatment of IRDS and ventilation
strategies applied in both HFV and CMV as important
sources of heterogeneity [4]. These associations could
be confounded by other explanatory variables. Although
a meta-analysis may pool results from randomized trials,
differences among trials will not be randomly or inde-
pendently distributed. A meta-analysis constitutes an
observational study of trials, subjected to bias inherent to
observational research. In a meta-regression analysis it is
possible to adjust for confounding covariates. A number
of alternative hypotheses have been formulated to explain
heterogeneity between trials:
1. The observed regression of the cumulative relative
risks to the level of unity was due to publication bias.
2. Use of the Sensormedics ventilator resulted in better
results in HFV treated patients.
3. AprolongedventilationonCMVbeforeinitiating HFV
treatment could reduce the beneﬁts of HFV.
4. In subgroups of more premature neonates with lower
birth weight with a higher susceptibility for CLD, HFV
could result in better pulmonary outcome.
5. With outcome rates increasingly representing more se-
vere disease, HFV could have an increasing advantage
over CMV [9, 10]; therefore, we used meta-regression
analysis to better estimate relative treatment effects
through adjustments for factors that could explain trial
heterogeneity.
Methods
Trials were included based on a previous meta-analysis
that we had conducted [4]. The same search strategy, as
well as the same inclusion and exclusion criteria as in our
previous meta-analysis, were used for an update, yield-
ing two more studies that could be included for this meta-
regressionanalysis.Validity ofstudieswas assessedbycri-
teria publishedbyJadadet al. [11].The validitywas gener-
ally deemed as high with adequate allocation concealment
in all trials. Blinding of treatment was not possible due to
the nature of the interventions.
Data extraction was performed as has been reported in
our previous meta-analysis. The following outcome meas-
ures were used: mortality, chronic lung disease (CLD)
as deﬁned by supplemental oxygen need or ventilator
dependency at the age of 30–36weeks post-menstrual.
A number of explanatory variables were extracted as
well: year of publication; type of ventilator used for HFV
(Sensormedics 3100A ventilator versus other); ventilation
strategies applied in the HFV and CMV treatment groups
were obtained as previously described [4]; time on CMV
before study initiation; gestational age and birth weight;
and outcome rates in the control population were taken as
proxy for baseline disease severity in the source popula-
tion. The Sensormedics ventilator was singled out because
previous research suggested better performance compared
with other oscillator ventilators [2, 4].
Statistical analysis
All data were extracted according to the intention-to-treat
principle. The number of patients surviving without
chronic lung disease was subtracted from the total number
of randomized patients in each treatment arm to calculate
the composite outcome of death or CLD. To calculate the
risk of CLD, the number of surviving patients was put in
the denominator. Publication bias was assessed by visual
appraisal of symmetry of funnel plots and performing
rank tests. Smaller studies could show different results
than larger studies which could suggest publication bias,
but in fact was caused by systematic differences among
studies; therefore, an analysis of publication bias stratiﬁed
for ventilation strategies was performed to determine
whether the observed association between the inverse of
the standard error with the risk ratio was confounded by
ventilation strategies. Meta-regression analysis was used
to evaluate other hypotheses. The dependent variables,
RR of CLD and RR of CLD or death, were natural log
transformed to linearize the regression models. Individual
studies were weighted by inverse variances of relative
risks of outcomes of interest so that the more precise
studies had more inﬂuence in the analysis. Firstly, linear
regression analyses were applied to explanatory variables.
Secondly, linear regression analyses with continuous
covariates were conducted stratiﬁed by HLVS, LPVS,
and use of surfactant. Finally, multivariable linear re-
gression analyses were performed to calculate adjusted
contributions of different explanatoryvariables of rivalling
hypotheses to changes in RR. The relative effects of
covariates were evaluated by relative risk ratios (RRR).
A relative risk ratio quantiﬁes the relative change in RR
that is associated with a speciﬁed change of a covariate.
For continuous variables the RRR was calculated for the
ranges of minimum and maximum values of covariates
that were reported in trials. For example, the RRR for
year of publication was calculated by using the range
between the publication year of the ﬁrst year and the
publication year of the last included trial. The RRR for
year of publication thus estimates the relative change in
RR due to the difference in years of publication between
the ﬁrst and last trials. All analyses were conducted using682
SPSS 12.0.1 for Windows software (SPSS, Chicago, Ill.)
and Excel (Microsoft, Redmond, Wash.).
Results
For the analyses15 studies were availablethat speciﬁed ei-
ther CLD in survivors or death or CLD as outcome meas-
ures [2, 3, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24]. In 11 trials a high frequency oscillatory ventilator was
used [2, 3, 12, 13, 16, 17, 19, 20, 22, 23, 24], in 7 of
these trials this was the SensorMedics ventilator [2, 12, 13,
17, 22, 23]. Two studies used a high-frequency jet ventila-
tor [14, 15] and in two studies a high-frequency ﬂow in-
terrupter ventilator was used [18, 21]. In the HFV group
a total of 1141 patients were included for the outcome of
CLD with 373 events and a total of 1457 patients with 671
events for the outcome death or CLD. In the CMV group
a total1159patientswerereportedfortheoutcomeofCLD
with428eventsandatotalof1473patientswith730events
for the outcome death or CLD. A forest plot of these trials
can be found in the Electronic Supplement.
Table1 summarizes the main characteristics of the
studies. The outcome of CLD was available in all studies
but one [22]. Time on CMV to start of the study was not
reported by Plavka et al. [17] and Craft et al. [21]. In
only one study was surfactant not used as concomitant
treatment [12]. A high lung volume strategy (HLVS)
was used in all but two studies [14, 16]. A ventilation
strategy in the CMV-treated patients that could qualify as
lung protective (LPVS) was reported in the most recent
9 studies [2, 3, 18, 19, 20, 21, 22, 23, 24]. Studies were
Table 1 Study characteristics
Time on Birth CLD Death
Reference Year CMV Age weight SensorM HLVS LPVS Surf lnRR Weight or CLD Weight
lnRR
[12] 1992 9.0 28 1.100 YYNN - 1 . 2 9 0 . 0 1 - 0 . 5 8 0 . 0 1
[13] 1996 3.0 31 1.500 YYNY - 0 . 6 7 0 . 0 4 - 0 . 5 5 0 . 0 2
[14] 1996 7.2 27 0.950 NNNY 0 . 0 2 0 . 0 1 - 0 . 2 3 0 . 1 0
[15] 1997 8.0 27 1.020 NYNY - 0 . 7 0 0 . 0 3 0 . 4 8 0 . 0 3
[16] 1998 1.0 28 1.100 NNNY 0 . 0 0 0 . 0 0 0 . 3 1 0 . 0 0
[17] 1999 26 0.850 YYNY - 1 . 0 3 0 . 0 1 - 0 . 7 4 0 . 0 1
[18] 1999 0.5 27 0.870 NYYY 0 . 0 9 0 . 0 6 0 . 0 1 0 . 0 4
[19] 2001 2.6 26 0.840 YYYY - 0 . 9 8 0 . 0 2 - 0 . 5 9 0 . 0 2
[20] 2001 0.3 28 0.990 NYYY - 0 . 2 0 0 . 0 5 - 0 . 0 6 0 . 0 5
[2] 2002 2.7 26 0.850 YYYY - 0 . 0 6 0 . 1 6 - 0 . 2 2 0 . 1 3
[3] 2002 1.0 26 0.850 NYYY - 0 . 0 1 0 . 5 4 - 0 . 0 2 0 . 6 0
[23] 2003 1.0 29 1.200 YYYY 0 . 3 2 0 . 0 3 0 . 2 7 0 . 0 4
[22] 2003 14.0 27 0.980 YYYY - 0 . 0 4 0 . 0 5
[21] 2003 26 0.726 NYYY 0 . 1 0 0 . 0 5 0 . 0 9 0 . 0 3
[24] 2005 0.3 27 0.880 NYYY - 1 . 4 4 0 . 0 1 - 1 . 2 0 0 . 0 0
Year: year of publication; Time CMV: Mean time on CMV before start of the study in hours; Age: Mean gestational age (weeks); Birth
weight: mean birth weight (kg); HLVS: high lung volume strategy in the HFV group; LPVS: lung protective ventilation strategy in the CMV
group; Surf: use of surfactant in the study; CLD: chronic lung disease, deﬁned as on oxygen at 30–36 weeks postmenstrual age; LnRR:
natural log of the relative risk
published over a range of 13years. Other reported ranges
of covariates were 8.7h average time on CMV before start
of study, 5weeks average gestational age, and 0.65kg
average birth weight. These ranges were used to calculate
RRRs. Two studies dominated the analyses by virtue of
the weight they received in the analyses: Johnson et al. [3]
and Courtney et al. [2] (together 69% for CLD and 73%
for death or CLD as outcome).
Afunnelplotoftheinverseofthestandarderroragainst
the natural logarithm of the RR for CLD was indicative of
publication bias because of asymmetry round the line of
the pooled effect (Fig. 1). A rank test showed a p-value of
0.112. A stratiﬁed analysis of publication bias is indicated
by different colors in Fig. 1. To visually evaluate publica-
tion bias within subgroups of ventilation strategy, the dis-
tribution of trials round the corresponding colored lines
(mean effect size within subgroup) was assessed. Strati-
ﬁcation by ventilation strategy (HLVS and LPVS vs either
no HLVS and/or no LPVS) showed p-values of 0.456 and
0.851, respectively, indicating less evidence of publication
bias. The distribution of stratiﬁed studies round the lines
of pooled estimates showed less asymmetry (Fig. 1). Pub-
lication bias for the composite outcome of death or CLD
was less likely with a p-value of 0.329. Stratiﬁed analysis
showed p-values of 0.677 and 1.000.
Figures2, 3, 4 show the results of the linear meta-
regression analyses for continuous explanatory variables
with relative risk of CLD as dependent variable. Two
studies dominate these ﬁgures, designated by the weight
they received in the analyses [2, 3]. Over the years the
reported beneﬁt of HFV over CMV seemed to diminish
(Fig.2). A longer time on CMV prior to study initiation683
Fig.1 Funnel plot. Selection bias in reporting RR of chronic lung
disease (CLD) as suggested by asymmetry of the distribution of
studies. x-axis: inverse of the standard error of the RR; y-axis: natu-
ral logarithm of the RR. Blue diamonds: studies with either no high
lung volume strategy (HLVS) or no lung protective volume strategy
(LPVS); pink diamonds: studies with both HLVS and LPVS; dotted
line: estimated pooled RR including all studies; dashed colored
lines: pooled RR of subgroups of studies. Publication bias was vis-
ually appraised by assessing symmetry of distribution of studies
around the lines of pooled estimates. CMV conventional mech-
anical ventilation
Fig.3 Same as Fig. 2
and a higher gestational age and increase of birth weight
(data not shown) seemed to be positively associated with
a relatively better outcome in HFV (Figs. 3, 4). Table2
shows the results of linear meta-regression analyses,
showing signiﬁcant associations with year of publication
(3.1 times higher RR with change of publication year
from 1992 to 2005) and whether or not a protective
ventilation strategy was applied (1.9 times higher RR with
change of protective ventilation from no to yes; Table 2).
In the linear regression analyses with death or CLD
as composite outcome no signiﬁcant associations were
detected. Whether or not a Sensormedics high-frequency
Fig.2 Linear regression analyses. Crude and subgroup linear re-
gression analyses of the effect of year of publication, prior time on
CMV and gestational age with natural logarithm of RR of CLD as
dependent variable. y-axis: natural logarithm of the RR; x-axis: ex-
planatory variables. Blue diamonds: studies with either no HLVS or
no LPVS; pink diamonds: studies with both HLVS and LPVS. The
size of the diamonds reﬂects the weights the individual trials con-
tribute to the analyses. Thin blue line: regression line including all
studies; thick pink line: regression line including only studies with
both HLVS and LPVS. CMV conventional mechanical ventilation
Fig.4 Same as Fig. 2
oscillatory ventilator was used and baseline incidence
in CMV (0.75 vs 0.08) treated patients displayed the
smallest effects on trial outcome (RRR =0.84 and 0.90
for CLD and RRR =0.85 and 0.99 for death or CLD,
respectively).
Figure5 shows how the incidence of CLD in the CMV
treatedpatients wasrelated to theincidencein HFV treated
patients for each of the studies. The diagonal line repre-
sents the line of no effect in this ﬁgure. A trend line was
ﬁtted by weighted linear regression, showing a small ef-
fect of change in incidence in CMV on incidence in HFV-
treated patients.684
Year of publication was not related to change in rela-
tive risk of CLD in the subgroup of studies with HLVS,
LPVS and concomitant use of surfactant (RRR =0.96).
There was only a small increase in relative risk for death
or CLD (RRR= 1.20; Fig. 2; Table2). Opposite effects of
gestational age (RRR = 1.22 for CLD and 1.38 for death
or CLD vs RRR = 0.66 for CLD and 0.91 for death or
CLD, respectively) and birth weight were detected in the
subgroup analysis (Fig.4; Table2). Prior time on CMV
exerted less effect on outcome compared with the crude
analysis, RRR = 0.66 for CLD and 0.96 for death or CLD
Table 2 Univariable linear regression analysis
95% conﬁdence interval 95% conﬁdence interval
Crude B Sig. Lower Upper RRR Lower Upper
boundary boundary boundary boundary
All studies
CLD
Year 0.09 0.025 0.01 0.16 3.13 1.18 8.27
SensorM -0.17 0.351 -0.55 0.21 0.84 0.58 1.24
( n ot oy e s )
TimeCMV -0.09 0.055 -0.19 0.00 0.44 0.19 1.02
Age -0.08 0.237 -0.23 0.06 0.66 0.32 1.36
Weight -0.76 0.163 -1.87 0.35 0.54 0.22 1.33
HLVS -0.11 0.883 -1.74 1.52 0.89 0.17 4.57
LPVS 0.64 0.009 0.19 1.10 1.91 1.21 3.00
Surf 1.21 0.168 -0.59 3.00 3.34 0.56 20.03
CMV -0.18 0.774 -1.53 1.17 0.90 0.42 1.92
Death or CLD
Year 0.05 0.096 -0.01 0.12 2.01 0.86 4.65
SensorM -0.17 0.132 -0.39 0.06 0.85 0.67 1.06
TimeCMV -0.01 0.590 -0.05 0.03 0.92 0.65 1.29
Age -0.02 0.733 -0.13 0.10 0.91 0.52 1.61
Weight -0.22 0.611 -1.16 0.71 0.84 0.40 1.77
HLVS -0.37 0.698 -2.44 1.69 0.69 0.09 5.45
LPVS 0.19 0.275 -0.18 0.56 1.21 0.84 1.76
Surf 0.52 0.289 -0.51 1.56 1.69 0.60 4.75
CMV -0.02 0.963 -0.91 0.87 0.99 0.60 1.63
Studies with surfactant, HLVS, and LPVS
CLD
Year 0.00 0.971 -0.23 0.22 0.96 0.05 17.34
TimeCMV -0.05 0.698 -0.34 0.25 0.66 0.05 8.75
Age 0.04 0.727 -0.22 0.30 1.22 0.33 4.49
Weight 0.41 0.693 -1.99 2.81 1.38 0.20 9.44
Death or CLD
Year 0.01 0.846 -0.15 0.17 1.20 0.15 9.72
TimeCMV 0.00 0.819 -0.05 0.04 0.96 0.65 1.43
Age 0.06 0.406 -0.10 0.21 1.34 0.61 2.92
Weight 0.55 0.396 -0.89 1.99 1.55 0.49 4.90
Simple linear regression analyses were calculated for chronic lung disease (CLD), deﬁned as on oxygen at 30–36weeks postgesta-
tional age, and death or CLD. The following co-variates were evaluated: Year: Number of years after the ﬁrst included study; Sen-
sorM: Whether or not a Sensormedics type of HFV was used; TimeCMV: Mean time on CMV before start of the study in hours;
Age: Mean gestational age (weeks); Weight: mean birth weight (kg); HLVS: high lung volume strategy in the HFV group; LPVS: lung
protective ventilation strategy in the CMV group; Surf: use of surfactant in the study; B was the estimated crude coefﬁcient; RRR:
relative risk ratio=RRcovariate=1/RRcovariate=0, for binary variables (SensorM, HLVS and LPVS), for continues variables the extreme
values reported in the studies were used to calculate the ranges, 13 for years, 8.7 for Time on CMV, 5 for Age, 0.8 for Weight and
0.65 for CMV (RRRyears =RRyear=2005/RRyear=1992,RRRtimeonCMV =RR time=9h/RRtime=0.3h, RRRage =RR age=31weeks/RRyear=26weeks,
RRRweight =RR weight=1.5 kg/RRyear=0.7kg, RRRincidenceo fCLDinCMV=0.75/RRincidence=0.08)
and RRR = 0.44 for CLD and 0.92 for death or CLD in the
adjusted and crude analyses, respectively (Fig.3; Table2).
Multivariable linear regression analyses were con-
ducted to assess the independent contributions to change
in RR by explanatory variables (Table 3). The RRRs
in Table3 have the same meaning as in Table2, only
they represented adjusted RRRs. Year of publication
was not considered as an independent explanatory vari-
able but rather as proxy for changes in treatment and
patient population. Gestational age and birth weight
were collinearly related by nature; only gestational age685
Table 3 Multivariable linear regression analysis
Adjusted 95% conﬁdence interval 95% conﬁdence interval
B Sig. Lower Upper RRR Lower Upper
boundary boundary boundary boundary
Model A
CLD
(Constant) -0.66 0.900 -13.03 11.70
SensorM -0.04 0.884 -0.75 0.66 0.96 0.47 1.94
TimeCMV -0.02 0.903 -0.38 0.34 0.85 0.04 19.22
Age 0.03 0.850 -0.36 0.42 1.17 0.16 8.32
HLVS -0.88 0.306 -2.80 1.04 0.42 0.06 2.84
LPVS 0.70 0.506 -1.73 3.14 2.02 0.18 23.12
Death or CLD
(Constant) -1.86 0.412 -7.22 3.49
SensorM -0.17 0.309 -0.55 0.21 0.85 0.58 1.24
TimeCMV 0.01 0.722 -0.05 0.06 1.07 0.68 1.69
Age 0.08 0.299 -0.09 0.25 1.47 0.62 3.47
HLVS -0.88 0.407 -3.38 1.62 0.42 0.03 5.06
LPVS 0.68 0.127 -0.28 1.65 1.98 0.76 5.19
Model B
CLD
(Constant) 0.07 0.904 -1.21 1.35
SensorM -0.06 0.698 -0.38 0.26 0.94 0.69 1.30
HLVS -0.81 0.203 -2.14 0.52 0.44 0.12 1.68
LPVS 0.72 0.011 0.21 1.23 2.06 1.23 3.43
Death or CLD
(Constant)
SensorM -0.11 0.318 -0.33 0.12 0.90 0.72 1.13
HLVS -0.79 0.363 -2.66 1.08 0.45 0.07 2.93
LPVS 0.46 0.089 -0.09 1.01 1.59 0.92 2.74
Multiple linear regression analyses were calculated for chronic lung disease (CLD), deﬁned as on oxygen at 30-36 weeks postgesta-
tional age, and death or CLD. The following co-variates were evaluated: SensorM whether or not a Sensormedics type of HFV was used;
TimeCMV mean time on CMV before start of the study (in hours). HLVS high lung volume strategy in the HFV group, LPVS lung protective
ventilation strategy in the CMV group. B was the adjusted estimated coefﬁcient. RRR relative risk ratio=RRcovariate=1/RRcovariate=0,f o r
binary variables (SensorM, HLVS and LPVS), for continues variables the extreme values reported in the studies were used, 8.7 for Time
on CMV (RRRage =RR age=31weeks/RRyear=26weeks)
Fig.5 Linear regression analysis of incidence of CLD in CMV on
incidence of CLD in HFV. y-axis: incidence of CLD in HFV; x-axis:
incidence of CLD in CMV. Thin pink line: regression line including
all studies
was ﬁtted in the model. One study contributed to the
fact that surfactant was not used; therefore, surfactant
was not used in the multiple linear regression analyses.
Two models were ﬁtted. ModelA used Sensormedics,
time on CMV, gestational age, HLVS, and LPVS as
covariates. The largest estimated effects were caused by
ventilation strategies, HLVS, and LPVS, adjusted for
use of Sensormedics ventilator, prior time on CMV, and
gestational age. These estimations were consistent for the
outcomes CLD (RRR = 0.42 and RRR= 2.02 for HLVS
and LPVS, respectively) and death or CLD (RRR = 0.42
and RRR= 1.98 fro HLVS and LPVS, respectively). Use
of a Sensormedics ventilator seemed to have a much
smaller effect on RR for outcome. The RRR of gestational
age, comparing 26weeks with 31weeks, for CLD and
death or CLD were larger (RRR = 1.17 and RRR = 1.47).
The effect of a difference in prior time on CMV of 8.7h
on CLD vs death or CLD was not consistent (RRR = 0.85
and RRR = 1.07, respectively).
A sensitivity analysis was conducted by ﬁtting a se-
cond model (modelB) with the most important variables,686
HLVS and LPVS, combined with whether or not a Sen-
sormedics ventilator was used. The reported RRRs were
comparable to those in the ﬁrst model. Type of ventila-
tor did not have a large effect compared with ventilation
strategies (RRR = 0.94 and RRR= 0.90). The HLVS was
associated with a decrease of the RRs comparing HFV
with CMV (RRR =0.44 and RRR= 0.45), while LPVS in-
creased the RRs to the line of no effect (RRR = 2.06 and
RRR = 1.59).
Discussion
Our meta-regression analysis showed a clear trend of
decreasing differences in pulmonary outcome between
HFV and CMV in randomized trials conducted in pre-
mature neonates with IRDS over the years. The most
likely hypothesis for this trend was the application of
a LPVS in the most recent studies. Use of surfactant could
also have a signiﬁcant contribution, but only one study
did not use surfactant [12]. In previous meta-analyses,
subgroup analyses or cumulative methods were used
to explore heterogeneity [4, 5, 7]. Subgroup analysis is
equivalent to meta-regression with a categorical trial-level
covariate. Considering subgroup analysis formally as
a meta-regression has advantages, since it focuses on
differences between subgroups as is appropriate, rather
than the effects in each subgroup separately. Furthermore,
it is appropriate to use meta-regression to explore sources
of heterogeneity, even if an initial overall test for hetero-
geneity is non-signiﬁcant. This test often has low power
and therefore a non-signiﬁcant result does not reliably
identify lack of heterogeneity [25].
Inthismeta-regressionanalysisweevaluatedinaquan-
titative way a number of hypotheses that were raised to
account for different results between randomized trials.
A relatively large proportion of well-conducted trials
were available for the analyses. For most explanatory
variables there were important differences among trials.
The effects of the two most important covariates, HLVS
and LPVS, were consistent in the different models and
were even increased in effect size by adjusting for other
covariates. None of the competing hypotheses were more
likely to inﬂuence results as shown by calculating the
RRRs. Common pitfalls in meta-regression analysis can
occur, such as multiple or post-hoc analyses, and lead
to data dredging and a high probability of false-positive
conclusions [25]. We, therefore, restricted our analyses to
a limited number of pre-speciﬁed explanatory covariates.
Publication bias was considered unlikely as an explan-
ation of the apparent diminishing relative effect of HFV.
Publication bias is selection bias. If trials are selectively
published either because of their size or because of signif-
icant results, this would result in an association between
trial size and/or precision and the trial outcome. Strictly
speaking, funnel plots probe whether studies with little
precision (small studies) give different results from studies
with greater precision (larger studies). Asymmetry in the
funnel plot may therefore result not from a systematic
under-reporting of negative trials but from an essential
difference between smaller and larger studies that arises
from inherent between-study heterogeneity [26]; thus,
if larger studies were also associated with changes in
ventilation strategies and these strategies resulted in
changes in reported RRs, the assumed publication bias
would be, in fact, a real association between ventilation
strategy and study outcome; therefore, we conditioned the
association between precision and effect size, presumably
caused by publication bias, on ventilation strategies. This
resulted in a lower p-value for publication bias and more
symmetrical distribution of studies in subgroups in the
funnel plots; therefore, what appeared to be publication
bias could also be explained by differences in ventilation
strategies related to both study size and observed relative
risks. However, it should be pointed out that the strength
of this evidence is difﬁcult to assess because fewer studies
in the subgroups automatically resulted in less power to
detect publication bias.
Other alternative hypothesesthat have been formulated
to explain differences among studies were also less
compatible with the evidence [9]. The type of ventilator,
Sensormedicsvs other types of high-frequencyventilators,
displayed RRR close to one. In the crude analyses, prior
time on CMV before study initiation showed contradictory
effects to what was hypothesized [10]. The adjusted
analyses showed conﬂicting results depending on the
outcome. Gestational age and birth weight could also
inﬂuence the magnitude of the effect of HFV compared
with CMV. In the adjusted analysis gestational age did not
change the RR for CLD but showed an increase of the RR
for less premature neonates. Finally, an increased risk of
CLD was not accompanied by a greater relative beneﬁt of
HFV as compared with CMV.
The observed effects of continuous variables, such as
time on CMV or gestational age, could be exaggerated by
small studies with outlying results. For the covariate, time
on CMV, the two largest studies showed results that were
compatible with the hypothesis that this had no important
impact on the results of these trials [2, 3]. The same fact
applied to the effect of baseline incidence of CLD or death
or CLD. Gestational age and weight were comparable be-
tween the two largest trials, which made it more difﬁcult to
ascertaintherelevanceofthehypothesisthatinsmallerand
more premature infants HFV performed better than CMV
treatment. The observed direction of the effect of gesta-
tional age and birth weight, however,was opposite to what
the hypothesispredicted. If gestational age was to be inter-
pretedasa higherrisk of acquiringCLD, onewouldexpect
that an increase in the incidence of CLD was associated
with a relatively lower incidence of CLD in HFV treated
patients; however, linear regression analysis showed per-
fectly equal increase in both treatment groups. Still, the687
possibility remains that the relationship with patient aver-
ages, such as gestational age and birth weight, across trials
was not the same as the relationship for patients within
trials, and therefore an effect of these patient characteris-
tics cannot be excluded but only considered in relation to
other covariates [25].
Similar ﬁndings of the effects of ventilation strategies
have been reported by us and other authors as well [4, 5];
however, meta-analyses are subject to bias when differ-
ences among trials are used to explain differences in re-
ported RRs. In this meta-regression analysis we were able
to estimate adjusted association measures, thereby dimin-
ishing the effectsof possibleconfounders/effect-modiﬁers.
By calculating less biased estimates of the effects of ven-
tilation strategies and the effect of using a Sensormedics
ventilator instead of other ventilators on the outcome in
the different HFV trials we were able to reinforce the hy-
pothesis that ventilation strategies are more important than
type of ventilator to prevent CLD.
The results of this meta-analysis stresses the impor-
tance of using appropriate ventilation strategies to prevent
ventilator-induced lung damage in a highly vulnerable
group of patients; therefore, in clinical practice the
question of how to use the ventilator is more important
than the question of which ventilator should be used. The
major theoretical advantage of HFV to CMV is delivery
of smaller tidal volumes to an optimally recruited lung.
As this meta-regression analysis did not conﬁrm that
subgroups of more premature neonates, avoidance of
CMV prior to initiating HFV, or neonates with higher
risk of CLD were more likely to beneﬁt form elective
HFV in IRDS, future research should be directed at
identifying patients in whom HFV does have a beneﬁt
over CMV. To improvethe robustness of these conclusions




In conclusion, conﬁning randomized trails to smaller or
more premature children with IRDS did not seem to re-
sult in better pulmonary outcomes of HFV compared with
CMV. A generally held opinion that a prolonged ventila-
tion time on CMV prior to initiating HFV diminished the
beneﬁts of HFV was not in agreementwith the current evi-
dence. The most important effects resulting in differences
amongtrialswereprobablycausedbyventilationstrategies
applied in HFV- and CMV-treated patients.
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